This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
BLS Jobs Up Big: 353K, 3.7% Unemployment
by Mark Vickery
353K new jobs created for January are nearly double the 180K or so analysts were looking for.
AbbVie (ABBV) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
4 Large Drug Stocks Trying to Survive the Industry Challenges
by Kinjel Shah
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.
AbbVie (ABBV) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 1.09% and 1.78%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) Beats Q4 Earnings Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 133.33% and 0.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q4 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unveiling AbbVie (ABBV) Q4 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of AbbVie (ABBV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
3 Stocks Enjoying Favorable Analyst Coverage
by Derek Lewis
All three of these stocks have seen upgrades from analysts in recent days. Is it time to buy?
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw AbbVie (ABBV) settling at $163.91, representing a -0.3% change from its previous close.
Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
by Zacks Equity Research
Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
AbbVie (ABBV) closed at $165.39 in the latest trading session, marking a +0.38% move from the prior day.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights Apple, AbbVie, Toyota Motor, Monster Beverage and General Motors
by Zacks Equity Research
Apple, AbbVie, Toyota Motor, Monster Beverage and General Motors are included in this Analyst Blog.
AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, AbbVie (ABBV) stood at $161.48, denoting a -0.57% change from the preceding trading day.
Q4 Earnings Season Scorecard and Analyst Reports for Apple, AbbVie & Toyota
by Sheraz Mian
Today's Research Daily features a real-time update on the Q4 earnings season and new research reports on Apple (AAPL), AbbVie (ABBV), Toyota Motor (TM) and others.
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FVD
Pharma Stock Roundup: MRK to Buy Harpoon, JNJ to Acquire Ambrx Biopharma & More
by Kinjel Shah
Merck (MRK) offers to acquire Harpoon for $680 million. J&J (JNJ) is set to acquire Ambrx Biopharma for approximately $2.0 billion
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
The latest trading day saw AbbVie (ABBV) settling at $162.31, representing a +0.55% change from its previous close.
Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis
by Zacks Equity Research
Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.
AbbVie (ABBV) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?